CDC, FDA Announce 77,000 Additional Doses for Nirsevimab as Infant Treatment of RSV

Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.

Related Keywords

United States ,American ,Patrizia Cavazzoni ,Vaccines For Children Program ,American Academy Of Pediatrics ,American College Of Obstetricians ,Centers For Disease ,Advisory Committee On Immunization Practices ,Children Program ,Drug Evaluation ,American College ,American Academy ,Additional Doses ,Disease Control ,Care Units ,Immunization Practices ,